Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor

Abhik Bandyopadhyay, Joseph K. Agyin, Long Wang, Yuping Tang, Xiufen Lei, Beryl M. Story, John E. Cornell, Bradley H Pollock, Gregory R. Mundy, Lu Zhe Sun

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) signaling has been shown to promote invasion and metastasis in various models of human cancers. In this study, we investigated the efficacy of a TGF-β type I receptor kinase inhibitor (TβRI-I) to limit early systemic metastases in an orthotopic xenograft model of lung metastasis and in an intracardiac injection model of experimental bone and lung metastasis using human breast carcinoma MDA-MB-435-F-L cells, a highly metastatic variant of human breast cancer MDA-MB-435 cells, expressing the enhanced green fluorescent protein (EGFP). Treatment of the cells with the TβRI-I had no effect on their growth but blocked TGF-β-stimulated expression of integrin αvβ 3 and cell migration in vitro. Systemic administration of the TβRI-I via i.p. injection effectively reduced the number and size of the lung metastasis in both orthotopic xenograft and experimental metastasis models with no effects on primary tumor growth rate compared with controls. TβRI-I treatment also reduced the incidence of widespread early skeletal metastases in the femur, tibia, mandible, and spine detected by whole-body EGFP fluorescence imaging. Tumor burden in femora and tibiae was also reduced after TβRI-I treatment as detected by histomorphometry analysis compared with the placebo controls. Our results indicate for the first time that abrogation of TGF-β signaling by systemic administration of the TβRI-I can inhibit both early lung and bone metastasis in animal model systems and suggest antimetastatic therapeutic potential of the TβRI-I.

Original languageEnglish (US)
Pages (from-to)6714-6721
Number of pages8
JournalCancer Research
Volume66
Issue number13
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Phosphotransferases
Neoplasm Metastasis
Lung
Tibia
Heterografts
Femur
Theoretical Models
Breast Neoplasms
Bone and Bones
Injections
Optical Imaging
Therapeutics
Growth
Tumor Burden
Mandible
Integrins
Cell Movement
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., ... Sun, L. Z. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Research, 66(13), 6714-6721. https://doi.org/10.1158/0008-5472.CAN-05-3565

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. / Bandyopadhyay, Abhik; Agyin, Joseph K.; Wang, Long; Tang, Yuping; Lei, Xiufen; Story, Beryl M.; Cornell, John E.; Pollock, Bradley H; Mundy, Gregory R.; Sun, Lu Zhe.

In: Cancer Research, Vol. 66, No. 13, 01.07.2006, p. 6714-6721.

Research output: Contribution to journalArticle

Bandyopadhyay, A, Agyin, JK, Wang, L, Tang, Y, Lei, X, Story, BM, Cornell, JE, Pollock, BH, Mundy, GR & Sun, LZ 2006, 'Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor', Cancer Research, vol. 66, no. 13, pp. 6714-6721. https://doi.org/10.1158/0008-5472.CAN-05-3565
Bandyopadhyay, Abhik ; Agyin, Joseph K. ; Wang, Long ; Tang, Yuping ; Lei, Xiufen ; Story, Beryl M. ; Cornell, John E. ; Pollock, Bradley H ; Mundy, Gregory R. ; Sun, Lu Zhe. / Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. In: Cancer Research. 2006 ; Vol. 66, No. 13. pp. 6714-6721.
@article{17bc9b2654b647f789bdd082222b3fae,
title = "Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor",
abstract = "Transforming growth factor-β (TGF-β) signaling has been shown to promote invasion and metastasis in various models of human cancers. In this study, we investigated the efficacy of a TGF-β type I receptor kinase inhibitor (TβRI-I) to limit early systemic metastases in an orthotopic xenograft model of lung metastasis and in an intracardiac injection model of experimental bone and lung metastasis using human breast carcinoma MDA-MB-435-F-L cells, a highly metastatic variant of human breast cancer MDA-MB-435 cells, expressing the enhanced green fluorescent protein (EGFP). Treatment of the cells with the TβRI-I had no effect on their growth but blocked TGF-β-stimulated expression of integrin αvβ 3 and cell migration in vitro. Systemic administration of the TβRI-I via i.p. injection effectively reduced the number and size of the lung metastasis in both orthotopic xenograft and experimental metastasis models with no effects on primary tumor growth rate compared with controls. TβRI-I treatment also reduced the incidence of widespread early skeletal metastases in the femur, tibia, mandible, and spine detected by whole-body EGFP fluorescence imaging. Tumor burden in femora and tibiae was also reduced after TβRI-I treatment as detected by histomorphometry analysis compared with the placebo controls. Our results indicate for the first time that abrogation of TGF-β signaling by systemic administration of the TβRI-I can inhibit both early lung and bone metastasis in animal model systems and suggest antimetastatic therapeutic potential of the TβRI-I.",
author = "Abhik Bandyopadhyay and Agyin, {Joseph K.} and Long Wang and Yuping Tang and Xiufen Lei and Story, {Beryl M.} and Cornell, {John E.} and Pollock, {Bradley H} and Mundy, {Gregory R.} and Sun, {Lu Zhe}",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-05-3565",
language = "English (US)",
volume = "66",
pages = "6714--6721",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor

AU - Bandyopadhyay, Abhik

AU - Agyin, Joseph K.

AU - Wang, Long

AU - Tang, Yuping

AU - Lei, Xiufen

AU - Story, Beryl M.

AU - Cornell, John E.

AU - Pollock, Bradley H

AU - Mundy, Gregory R.

AU - Sun, Lu Zhe

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Transforming growth factor-β (TGF-β) signaling has been shown to promote invasion and metastasis in various models of human cancers. In this study, we investigated the efficacy of a TGF-β type I receptor kinase inhibitor (TβRI-I) to limit early systemic metastases in an orthotopic xenograft model of lung metastasis and in an intracardiac injection model of experimental bone and lung metastasis using human breast carcinoma MDA-MB-435-F-L cells, a highly metastatic variant of human breast cancer MDA-MB-435 cells, expressing the enhanced green fluorescent protein (EGFP). Treatment of the cells with the TβRI-I had no effect on their growth but blocked TGF-β-stimulated expression of integrin αvβ 3 and cell migration in vitro. Systemic administration of the TβRI-I via i.p. injection effectively reduced the number and size of the lung metastasis in both orthotopic xenograft and experimental metastasis models with no effects on primary tumor growth rate compared with controls. TβRI-I treatment also reduced the incidence of widespread early skeletal metastases in the femur, tibia, mandible, and spine detected by whole-body EGFP fluorescence imaging. Tumor burden in femora and tibiae was also reduced after TβRI-I treatment as detected by histomorphometry analysis compared with the placebo controls. Our results indicate for the first time that abrogation of TGF-β signaling by systemic administration of the TβRI-I can inhibit both early lung and bone metastasis in animal model systems and suggest antimetastatic therapeutic potential of the TβRI-I.

AB - Transforming growth factor-β (TGF-β) signaling has been shown to promote invasion and metastasis in various models of human cancers. In this study, we investigated the efficacy of a TGF-β type I receptor kinase inhibitor (TβRI-I) to limit early systemic metastases in an orthotopic xenograft model of lung metastasis and in an intracardiac injection model of experimental bone and lung metastasis using human breast carcinoma MDA-MB-435-F-L cells, a highly metastatic variant of human breast cancer MDA-MB-435 cells, expressing the enhanced green fluorescent protein (EGFP). Treatment of the cells with the TβRI-I had no effect on their growth but blocked TGF-β-stimulated expression of integrin αvβ 3 and cell migration in vitro. Systemic administration of the TβRI-I via i.p. injection effectively reduced the number and size of the lung metastasis in both orthotopic xenograft and experimental metastasis models with no effects on primary tumor growth rate compared with controls. TβRI-I treatment also reduced the incidence of widespread early skeletal metastases in the femur, tibia, mandible, and spine detected by whole-body EGFP fluorescence imaging. Tumor burden in femora and tibiae was also reduced after TβRI-I treatment as detected by histomorphometry analysis compared with the placebo controls. Our results indicate for the first time that abrogation of TGF-β signaling by systemic administration of the TβRI-I can inhibit both early lung and bone metastasis in animal model systems and suggest antimetastatic therapeutic potential of the TβRI-I.

UR - http://www.scopus.com/inward/record.url?scp=33746145265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746145265&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3565

DO - 10.1158/0008-5472.CAN-05-3565

M3 - Article

VL - 66

SP - 6714

EP - 6721

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -